Literature DB >> 32425395

Paratrabecular myelofibrosis and occult mastocytosis are strong morphological clues to suspect FIP1L1-PDGFRA translocation in hypereosinophilia.

Sreejesh Sreedharanunni1, Man Updesh Singh Sachdeva1, Saniya Sharma1, Sonia Rana1, Rajeev Sandal2, Narender Kumar1, Prashant Sharma1, Shano Naseem1, Jasmina Ahluwalia1, Reena Das1, Pankaj Malhotra2, Neelam Varma1.   

Abstract

To study the clinico-haematological and histopathological characteristics of FIP1L1-PDGFRA rearranged hypereosinophilia/hypereosinophilic syndrome (F/P+ve HE/HES), a retrospective analysis of patients with F/P+ve HE diagnosed over a period of 43 months was performed. Peripheral blood smears, bone marrow aspirate (BMA) and biopsies (BMB) were reviewed in each case and; reticulin stain and immunohistochemistry for mast cell tryptase (MCT) and CD117 was performed. F/P+ve HE was diagnosed in a total of ten patients during study period. All patients were males with a median age of 36 years (23-44 years). The median duration of presenting complaints was 7 months (2 months-3 years) which included specific symptoms related to various organs (80% of cases). Anaemia, thrombocytopenia and splenomegaly were seen in 60%, 50% and 90% of the cases respectively. Mastocytosis was not obvious in BMA but identified by MCT on BMB in all cases. Myelofibrosis (grade ≥ 1) was seen in 80% of the cases and includes multifocal paratrabecular fibrosis in 50% of the biopsies. Our study shows that bone marrow mastocytosis and myelofibrosis are very useful morphological indicators to suspect F/P+ve HE and suggests the routine use of reticulin staining and MCT immunohistochemistry in all BMBs performed for the evaluation of HE/HES. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  FIP1L1-PDGFRA rearrangement; Hypereosinophilia; Mast cell tryptase; Mastocytosis; Myelofibrosis

Year:  2019        PMID: 32425395      PMCID: PMC7229073          DOI: 10.1007/s12288-019-01236-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  16 in total

1.  Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?

Authors:  Ayalew Tefferi; Animesh Pardanani; Chin-Yang Li
Journal:  Blood       Date:  2003-10-15       Impact factor: 22.113

2.  The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.

Authors:  Annette Hildegard Schmitt-Graeff; Philipp Erben; Juliane Schwaab; Beate Vollmer-Kary; Georgia Metzgeroth; Karl Sotlar; Hans-Peter Horny; Hans-H Kreipe; Paul Fisch; Andreas Reiter
Journal:  Blood       Date:  2014-01-23       Impact factor: 22.113

3.  Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.

Authors:  Upendra Srinivas; Adarsh Barwad; Sushma Venkata Pubbaraju
Journal:  Br J Haematol       Date:  2014-01-24       Impact factor: 6.998

4.  The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

Authors:  Roberta La Starza; Giorgina Specchia; Antonio Cuneo; Donatella Beacci; Chiara Nozzoli; Luigiana Luciano; Anna Aventin; Constantina Sambani; Nicoletta Testoni; Marco Foppoli; Rosangela Invernizzi; Peter Marynen; Massimo F Martelli; Cristina Mecucci
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

5.  Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.

Authors:  J L Schaller; G A Burkland
Journal:  MedGenMed       Date:  2001-09-07

6.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

7.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Authors:  Animesh Pardanani; Rhett P Ketterling; Stephanie R Brockman; Heather C Flynn; Sarah F Paternoster; Brandon M Shearer; Terra L Reeder; Chin-Yang Li; Nicholas C P Cross; Jan Cools; D Gary Gilliland; Gordon W Dewald; Ayalew Tefferi
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

Review 8.  Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.

Authors:  J Gotlib; J Cools
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

9.  FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India.

Authors:  Anıl N Kumar; Vishwanath Sathyanarayanan; Visweswariah Lakshmi Devi; Namratha N Rajkumar; Umesh Das; Sarjana Dutt; Lakshmaiah K Chinnagiriyappa
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

10.  The Spectrum of Hypereosinophilia and Associated Clonal Disorders - A Real-World Data Based on Combined Retrospective and Prospective Analysis from a Tropical Setting.

Authors:  Sreejesh Sreedharanunni; Neelam Varma; Man Updesh Singh Sachdeva; Shano Naseem; Pankaj Malhotra; Deepak Bansal; Amita Trehan; Subhash Varma
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.